Quantitative effect of glycaemic improvement on the components of diabetic dyslipidaemia:: a longitudinal study

被引：6

作者：

Wägner, AM ^{[1
]}

Ordóñez-Llanos, J ^{[1
]}

Caixàs, A ^{[1
]}

Bonet, R ^{[1
]}

de Leiva, A ^{[1
]}

Pérez, A ^{[1
]}

机构：

[1] Hosp Sant Pau, Serv Endocrinol, Barcelona 08025, Spain

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2005年 / 68卷 / 01期

关键词：

type; 2; diabetes; glycaemic control; diabetic dyslipidaemia;

D O I：

10.1016/j.diabres.2004.07.018

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In order to assess the effect of glycaemic improvement on lipoprotein concentrations, we studied 73 type 2 diabetic subjects before (HbA(1c) 10.1 (6.2-16)%) and after (HbA(1c) 6.6 (3.8-8.0)%) glycaernic improvement. Total triglyceride and cholesterol (c), LDLc, HDLc, non-HDLc and apolipoproteins AI (apoAI) and B (apoB) were measured. Bivariate correlations and step-wise, multivariate analysis were performed to find predictors of change in the different components of diabetic dyslipidaemia. Changes in HDLc (r= -0.358, P=0.001), apoAI (r= -0.355, P=0.003), apoAI/apoB ratio (r= -0.333,P=0.005), weight (r= -0.245, P=0.046) and BMI (r= -0.253,P=0.039) correlated with that of HbAlc, but, in multivariate analysis, only changes in HDLc, apoAI and apoAI/apoB ratio were predicted by the decrease in HbAlc. For the median observed change in HbAlc (-3.3 percentage-points), the estimated changes were +0.14 mmol/l, +0. 12 g/l and +0.20 for HDLc, apoAI and apoAI/apoB ratio, respectively, accounting for 81, 92 and 80% of the observed changes. In conclusion, for the component of diabetic dyslipidaemia for which less therapeutic tools are available, glycaemic improvement is most effective. (c) 2004 Elsevier Ireland Ltd. All rights reserved.

引用

页码：81 / 83

页数：3

共 5 条

[1] Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients [J].

Caixas, A ;

OrdonezLlanos, J ;

deLeiva, A ;

Payes, A ;

Homs, R ;

Perez, A .

DIABETES, 1997, 46 (07) :1207-1213

[2] Lack of change of lipoprotein(a) levels by the optimization of glycemic control with insulin therapy in NIDDM patients [J].

Caixas, A ;

Perez, A ;

OrdonezLlanos, J ;

Bonet, R ;

Rigla, M ;

Castellvi, A ;

Bayen, L ;

DeLeiva, A .

DIABETES CARE, 1997, 20 (09) :1459-1461

[3] The Veterans Affairs Implantable Insulin Pump Study - Effect on cardiovascular risk factors [J].

Duckworth, WC ;

Saudek, CD ;

Giobbie-Hurder, A ;

Henderson, WG ;

Henry, RR ;

Kelley, DE ;

Edelman, SV ;

Zieve, FJ ;

Adler, RA ;

Anderson, JW ;

Anderson, RJ ;

Hamilton, BP ;

Donner, TW ;

Kirkman, MS ;

Morgan, NA .

DIABETES CARE, 1998, 21 (10) :1596-1602

[4] Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins -: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus [J].

Emanuele, N ;

Azad, N ;

Abraira, C ;

Henderson, W ;

Colwell, J ;

Levin, S ;

Nuttall, F ;

Comstock, J ;

Sawin, C ;

Silbert, C ;

Marcovina, S ;

Lee, HS .

ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (22) :2485-2490

[5] The impact of outpatient diabetes management on serum lipids in urban African-Americans with type 2 diabetes [J].

Erdman, DM ;

Cook, CB ;

Greenlund, KJ ;

Giles, WH ;

El-Kebbi, I ;

Ryan, GJ ;

Gallina, DL ;

Ziemer, DC ;

Dunbar, VG ;

Phillips, LS .

DIABETES CARE, 2002, 25 (01) :9-15

← 1 →